Global Swine Live Vaccine Market Outlook, InDepth Analysis & Forecast to 2032豚用生ワクチンの世界市場 2026-2032年 The global Swine Live Vaccine market is projected to grow from US$ 962 million in 2025 to US$ 1265 million by 2032, at a CAGR of 4.2% (2026-2032), driven by critical product segments and diverse en... もっと見る
図表リストList of TablesTable 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Swine Live Vaccine Revenue by Region (US$ Million), 2021-2026 Table 7. Global Swine Live Vaccine Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Swine Live Vaccine Revenue by Players (US$ Million), 2021-2026 Table 10. Global Swine Live Vaccine Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Swine Live Vaccine Revenue, 2025 Table 13. Global Swine Live Vaccine Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Swine Live Vaccine Companies Headquarters Table 15. Global Swine Live Vaccine Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Swine Live Vaccine Revenue by Type (US$ Million), 2021-2026 Table 19. Global Swine Live Vaccine Revenue by Type (US$ Million), 2027-2032 Table 20. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026 Table 21. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032 Table 22. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2021-2026 Table 23. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Swine Live Vaccine Revenue by Application (US$ Million), 2021-2026 Table 26. Global Swine Live Vaccine Revenue by Application (US$ Million), 2027-2032 Table 27. Swine Live Vaccine High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Swine Live Vaccine Growth Accelerators and Market Barriers Table 31. North America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Swine Live Vaccine Growth Accelerators and Market Barriers Table 33. Europe Swine Live Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Swine Live Vaccine Growth Accelerators and Market Barriers Table 35. Asia-Pacific Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Swine Live Vaccine Investment Opportunities and Key Challenges Table 37. Central and South America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Swine Live Vaccine Investment Opportunities and Key Challenges Table 39. Middle East and Africa Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. Zoetis Corporation Information Table 41. Zoetis Description and Major Businesses Table 42. Zoetis Product Features and Attributes Table 43. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Zoetis Revenue Proportion by Product in 2025 Table 45. Zoetis Revenue Proportion by Application in 2025 Table 46. Zoetis Revenue Proportion by Geographic Area in 2025 Table 47. Zoetis Swine Live Vaccine SWOT Analysis Table 48. Zoetis Recent Developments Table 49. MSD Animal Health(Merck) Corporation Information Table 50. MSD Animal Health(Merck) Description and Major Businesses Table 51. MSD Animal Health(Merck) Product Features and Attributes Table 52. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. MSD Animal Health(Merck) Revenue Proportion by Product in 2025 Table 54. MSD Animal Health(Merck) Revenue Proportion by Application in 2025 Table 55. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025 Table 56. MSD Animal Health(Merck) Swine Live Vaccine SWOT Analysis Table 57. MSD Animal Health(Merck) Recent Developments Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Major Businesses Table 60. Boehringer Ingelheim Product Features and Attributes Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025 Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025 Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025 Table 65. Boehringer Ingelheim Swine Live Vaccine SWOT Analysis Table 66. Boehringer Ingelheim Recent Developments Table 67. Ceva Santé Animale Corporation Information Table 68. Ceva Santé Animale Description and Major Businesses Table 69. Ceva Santé Animale Product Features and Attributes Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025 Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025 Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025 Table 74. Ceva Santé Animale Swine Live Vaccine SWOT Analysis Table 75. Ceva Santé Animale Recent Developments Table 76. Bioveta Corporation Information Table 77. Bioveta Description and Major Businesses Table 78. Bioveta Product Features and Attributes Table 79. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Bioveta Revenue Proportion by Product in 2025 Table 81. Bioveta Revenue Proportion by Application in 2025 Table 82. Bioveta Revenue Proportion by Geographic Area in 2025 Table 83. Bioveta Swine Live Vaccine SWOT Analysis Table 84. Bioveta Recent Developments Table 85. HIPRA Corporation Information Table 86. HIPRA Description and Major Businesses Table 87. HIPRA Product Features and Attributes Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. HIPRA Recent Developments Table 90. Syva Corporation Information Table 91. Syva Description and Major Businesses Table 92. Syva Product Features and Attributes Table 93. Syva Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Syva Recent Developments Table 95. Elanco Animal Health Corporation Information Table 96. Elanco Animal Health Description and Major Businesses Table 97. Elanco Animal Health Product Features and Attributes Table 98. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Elanco Animal Health Recent Developments Table 100. TECON Biology Corporation Information Table 101. TECON Biology Description and Major Businesses Table 102. TECON Biology Product Features and Attributes Table 103. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. TECON Biology Recent Developments Table 105. VETVACO Corporation Information Table 106. VETVACO Description and Major Businesses Table 107. VETVACO Product Features and Attributes Table 108. VETVACO Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. VETVACO Recent Developments Table 110. Harbin Pharmaceutical Group Corporation Information Table 111. Harbin Pharmaceutical Group Description and Major Businesses Table 112. Harbin Pharmaceutical Group Product Features and Attributes Table 113. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Harbin Pharmaceutical Group Recent Developments Table 115. CAHIC Corporation Information Table 116. CAHIC Description and Major Businesses Table 117. CAHIC Product Features and Attributes Table 118. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. CAHIC Recent Developments Table 120. Jinyu Bio-Technology Corporation Information Table 121. Jinyu Bio-Technology Description and Major Businesses Table 122. Jinyu Bio-Technology Product Features and Attributes Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Jinyu Bio-Technology Recent Developments Table 125. Pulike Corporation Information Table 126. Pulike Description and Major Businesses Table 127. Pulike Product Features and Attributes Table 128. Pulike Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Pulike Recent Developments Table 130. WINSUN Corporation Information Table 131. WINSUN Description and Major Businesses Table 132. WINSUN Product Features and Attributes Table 133. WINSUN Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. WINSUN Recent Developments Table 135. DHN Corporation Information Table 136. DHN Description and Major Businesses Table 137. DHN Product Features and Attributes Table 138. DHN Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. DHN Recent Developments Table 140. HVRI Corporation Information Table 141. HVRI Description and Major Businesses Table 142. HVRI Product Features and Attributes Table 143. HVRI Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. HVRI Recent Developments Table 145. Jilin Zhengye Corporation Information Table 146. Jilin Zhengye Description and Major Businesses Table 147. Jilin Zhengye Product Features and Attributes Table 148. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Jilin Zhengye Recent Developments Table 150. Wuhan Keqian Biology Corporation Information Table 151. Wuhan Keqian Biology Description and Major Businesses Table 152. Wuhan Keqian Biology Product Features and Attributes Table 153. Wuhan Keqian Biology Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Wuhan Keqian Biology Recent Developments Table 155. Sinopharm Animal Health Corporation Information Table 156. Sinopharm Animal Health Description and Major Businesses Table 157. Sinopharm Animal Health Product Features and Attributes Table 158. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Sinopharm Animal Health Recent Developments Table 160. Technologies, Platforms and Infrastructure Table 161. Distributors List Table 162. Market Trends and Market Evolution Table 163. Market Drivers and Opportunities Table 164. Market Challenges, Risks, and Restraints Table 165. Research Programs/Design for This Report Table 166. Key Data Information from Secondary Sources Table 167. Key Data Information from Primary Sources List of Figures Figure 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. PRRS Vaccines Product Picture Figure 3. Classical Swine Fever Vaccines Product Picture Figure 4. Pseudorabies Vaccines Product Picture Figure 5. Others Product Picture Figure 6. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Figure 7. Monovalent Live Vaccines Product Picture Figure 8. Bivalent Live Vaccines Product Picture Figure 9. Multivalent Live Vaccines Product Picture Figure 10. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Figure 11. Lyophilized Live Vaccines Product Picture Figure 12. Liquid Live Vaccines Product Picture Figure 13. Others Product Picture Figure 14. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 15. Piglets Figure 16. Growing and Finishing Pigs Figure 17. Breeding Sows and Gilts Figure 18. Breeding Boars Figure 19. Others Figure 20. Swine Live Vaccine Report Years Considered Figure 21. Global Swine Live Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 22. Global Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 23. Global Swine Live Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 24. Global Swine Live Vaccine Revenue-Based Market Share by Region (2021-2032) Figure 25. Global Swine Live Vaccine Revenue-Based Market Share Ranking (2025) Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 27. PRRS Vaccines Revenue-Based Market Share by Player in 2025 Figure 28. Classical Swine Fever Vaccines Revenue-Based Market Share by Player in 2025 Figure 29. Pseudorabies Vaccines Revenue-Based Market Share by Player in 2025 Figure 30. Others Revenue-Based Market Share by Player in 2025 Figure 31. Global Swine Live Vaccine Revenue-Based Market Share by Type (2021-2032) Figure 32. Global Swine Live Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032) Figure 33. Global Swine Live Vaccine Revenue-Based Market Share by Dosage Form (2021-2032) Figure 34. Global Swine Live Vaccine Revenue-Based Market Share by Application (2021-2032) Figure 35. North America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 36. North America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 37. North America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 38. US Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 39. Canada Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 40. Mexico Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 41. Europe Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 42. Europe Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 43. Europe Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 44. Germany Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 45. France Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 46. U.K. Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 47. Italy Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 48. Russia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 49. Asia-Pacific Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 50. Asia-Pacific Top 8 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 51. Asia-Pacific Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 52. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 53. Japan Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 54. South Korea Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 55. Australia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 56. India Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 57. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 58. Vietnam Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 59. Malaysia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 60. Philippines Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 61. Singapore Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 62. Central and South America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 63. Central and South America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 64. Central and South America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 65. Brazil Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 66. Argentina Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 67. Middle East and Africa Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 68. Middle East and Africa Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 69. Middle East and Africa Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 70. GCC Countries Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 71. Israel Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 72. Egypt Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 73. South Africa Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 74. Swine Live Vaccine Value Chain Mapping Figure 75. Channels of Distribution (Direct Vs Distribution) Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed
SummaryThe global Swine Live Vaccine market is projected to grow from US$ 962 million in 2025 to US$ 1265 million by 2032, at a CAGR of 4.2% (2026-2032), driven by critical product segments and diverse end‑use applications.Swine Live Vaccines are veterinary biological products containing live viruses, bacteria, or other microorganisms that have been attenuated while retaining limited replication capability and immunogenicity and are used to induce active immunity against specific infectious diseases in pigs. The major disease categories include PRRS Vaccines, Classical Swine Fever Vaccines, Pseudorabies Vaccines, and Others. By Antigen Combination, the product is classified into Monovalent Live Vaccines, Bivalent Live Vaccines, and Multivalent Live Vaccines; by Dosage Form, into Lyophilized Live Vaccines, Liquid Live Vaccines, and Others, with lyophilized formulations being the most widely commercialized. Manufacturing generally uses master- and working-seed systems followed by cell culture or other suitable biological substrate propagation, attenuated-strain cultivation, harvesting, stabilization, lyophilization or liquid filling, and potency testing. Core parameters include TCID50, PFU or CFU potency, attenuation stability, genetic stability, onset and duration of immunity, maternal-antibody interference, and storage conditions. Key Findings The average industry gross margin in 2025 is approximately 40%–60%. PRRS Vaccines represent the largest value segment, with representative modified-live products providing approximately 10^4.8 TCID50 per dose at an injection volume of around 1–2 mL. Piglets represent the largest downstream application, with mainstream modified-live PRRS products commonly administered from one day to three weeks of age or older. Zoetis, MSD Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and HIPRA are positioned among the major global suppliers. Market Trends The product is evolving from conventionally attenuated strains toward genetically engineered attenuation, improved genetic stability, needle-free intradermal administration, and digital vaccination management. PRRS remains the most innovation-intensive field. Ceva's next-generation PRRSV2 modified-live platform uses reverse genetics and Synthetic Attenuated Virus Engineering to improve genetic stability and heterologous protection, while HIPRA combines a lyophilized PRRS live vaccine with 0.2 mL needle-free intradermal administration, RFID labeling, and digital vaccination records. For Classical Swine Fever, conventional C-strain vaccines remain established, but DIVA-compatible live-marker technologies and molecular differentiation are increasingly important in eradication-oriented regions. Market Dynamics Drivers Demand for the product is mainly driven by large-scale swine production, persistent endemic PRRS, piglet health management, and protection of reproductive performance in breeding herds. PRRSV is endemic across most major swine-producing regions and can cause reproductive failure, piglet mortality, respiratory disease, and reduced growth, making vaccination an important component of long-term herd control together with internal biosecurity. Modified-live PRRS vaccines address both respiratory and reproductive manifestations. Fostera PRRS can be used in susceptible pigs one day of age or older, Prevacent PRRS in pigs two weeks of age or older, and Ingelvac PRRS MLV is commonly used in piglets three weeks of age or older as well as replacement gilts and adult sows, creating demand across multiple production stages. Restraints The main restraints are vaccine-strain shedding, recombination and genetic-stability concerns, together with substantial differences in circulating strains and herd immunity. Modified-live PRRS strains can replicate and be shed by vaccinated animals, and both Zoetis and Elanco warn that vaccine virus may be transmitted to pigs in direct or indirect contact with vaccinated animals, making such products unsuitable for herds intended to remain PRRS-negative. PRRSV itself has high genetic diversity and recombination potential, complicating vaccination programs where field and vaccine strains coexist. Conventional Classical Swine Fever live vaccines also have limitations during eradication because standard antibody testing cannot always distinguish infected from vaccinated animals, increasing interest in DIVA technologies and post-vaccination surveillance. Opportunities Future opportunities are concentrated in next-generation modified-live PRRS platforms, needle-free intradermal vaccination, DIVA live-marker vaccines, and Bivalent or Multivalent products. HIPRA's UNISTRAIN PRRS can be administered as a 2 mL intramuscular dose or a 0.2 mL intradermal dose and can be integrated with digital vaccination devices. Ceva's next-generation PRRSV2 platform differentiates through reverse genetics and engineered attenuation. In Antigen Combination, Bivalent and Multivalent live vaccines can reduce handling and administration frequency. Bioveta commercializes a live Bivalent product combining Classical Swine Fever and swine erysipelas, containing at least approximately 1×10^9 live Erysipelothrix organisms and at least 10^5 PD50 of Classical Swine Fever antigen. Platforms combining multi-disease protection, low-dose administration, and digital traceability offer high value potential. Challenges The core challenge is simultaneously achieving adequate attenuation, stable immunogenicity, and low risk of recombination or reversion to virulence. PRRSV comprises the distinct PRRSV-1 and PRRSV-2 species, with substantial internal genetic diversity, and multiple variants may circulate within the same farm, limiting the ability of a single vaccine to cover every heterologous challenge. Modified-live strains can also participate in recombination, requiring strict internal biosecurity and disciplined vaccination programs. Classical Swine Fever live vaccines similarly require long-term validation of master-seed purity, genetic stability, and reversion-to-virulence risk. WOAH requires production under a seed-lot system and has strengthened safety requirements for conventional and live-marker vaccines. Future competition will increasingly depend on genomic-stability validation, cross-protection data, and post-market surveillance. Industry Chain Analysis The upstream supply chain mainly includes master and working seed stocks, animal cell lines and culture media, bioreactors, stabilizers, lyophilization protectants, sterile diluents, culture consumables, glass vials, and cold-chain packaging. Seed purity, cell-substrate safety, and culture yield determine fundamental product quality. Midstream activities include attenuated-strain selection or engineering, cell-culture propagation, virus or bacterial harvesting, clarification and concentration, potency standardization, stabilizer formulation, lyophilization or liquid filling, sterility and extraneous-agent testing, genetic-stability assessment, and batch release. WOAH requires Classical Swine Fever live vaccines to be manufactured using a seed-lot system and qualified cell culture, with commercial vaccine commonly formulated as a homogeneous lyophilized product. Downstream demand comes from Piglets, Growing and Finishing Pigs, Breeding Sows and Gilts, Breeding Boars, and Others through integrated swine farms, veterinary distributors, and veterinary service networks, supported by cold chain, vaccination-program design, antibody/PCR monitoring, and digital herd-health management. Segment Insights By disease type and Dosage Form, PRRS Vaccines represent the most important value segment, with Lyophilized modified-live products being the mainstream technology. A representative Boehringer Ingelheim product contains at least 10^4.8 TCID50 of attenuated VR-2332 strain per dose and is administered at 2 mL intramuscularly. Syva Pyrsvac-183 contains attenuated European strain ALL183 at ≥10^5 TCID50, uses a 2 mL dose, provides onset of immunity at approximately two weeks, and duration of immunity of approximately 16 weeks. Classical Swine Fever live products typically use established attenuated strains such as the C strain; Bioveta provides approximately 100–10,000 TCID50 per dose at 2 mL intramuscularly, with immunity developing within approximately five to seven days. By Antigen Combination, Monovalent Live Vaccines remain dominant, particularly where PRRS, Classical Swine Fever, or Pseudorabies vaccination programs need to be adjusted independently. Bivalent products reduce administration frequency, while Multivalent Live Vaccines remain a smaller category because of strain-stability, antigen-interference, and registration complexity. By Dosage Form, Lyophilized Live Vaccines dominate because of their relatively favorable long-term stability and are widely used in PRRS, Classical Swine Fever, and Pseudorabies products. Liquid Live Vaccines account for a smaller share and depend more heavily on stable liquid formulations and strict cold-chain handling. Emerging opportunities include 0.2 mL intradermal vaccination, engineered attenuation, DIVA markers, and more stable combination-live platforms. Downstream Market Opportunities Piglets represent the largest application because respiratory PRRS is frequently expressed in nursery and young finisher populations, encouraging early immunization from one day, two weeks, or three weeks of age depending on the product. Growing and Finishing Pigs require continuing respiratory-disease control to protect average daily gain and mortality performance. Breeding Sows and Gilts are vaccinated primarily to reduce abortion, premature farrowing, stillbirths, weak-born piglets, and other reproductive losses, with selected products used before breeding or during pregnancy. Use in Breeding Boars is more restricted, and some modified-live PRRS labels specifically advise against vaccination of breeding-age boars. Artificial intelligence is not part of the vaccine itself, but it can integrate PCR, antibody, production, abortion, mortality, and epidemiological data to predict infection risk, optimize vaccination timing, identify vaccine-breakthrough events, and improve batch and animal-level traceability through digital vaccination systems. Regional Insights North America is strongly focused on modified-live PRRS products, with Zoetis, MSD Animal Health, Boehringer Ingelheim, and Elanco maintaining established portfolios. The United States and Canada are free from Classical Swine Fever, significantly limiting commercial use of Classical Swine Fever live vaccines. Europe similarly emphasizes PRRSV-1 control, while many countries have WOAH-recognized Classical Swine Fever-free status, making PRRS an important source of live-vaccine demand; HIPRA, Bioveta, and Syva have substantial regional capabilities. Asia has a more complex disease profile, with commercial demand for PRRS, Classical Swine Fever, and Pseudorabies products. Chinese participants include TECON Biology, Harbin Pharmaceutical Group, CAHIC, Jinyu Bio-Technology, Pulike, WINSUN, DHN, HVR, Jilin Zhengye, Wuhan Keqian Biology, and Sinopharm Animal Health. WOAH indicates that Classical Swine Fever remains present principally in parts of Asia, Latin America, Europe, and Africa, creating a strongly regionalized vaccine-demand pattern. Competitive Landscape Analysis The product market has substantial barriers in seed-strain resources, cell-culture capability, biosafety, cold-chain management, clinical testing, and regulatory approval. Representative leading players include Zoetis, MSD Animal Health, Boehringer Ingelheim, Ceva Santé Animale, and HIPRA. Zoetis competes through Fostera PRRS, which can be used in pigs one day of age or older and provides at least 26 weeks of respiratory immunity. MSD's Prime Pac PRRS RR uses a convenient 1 mL dose and covers pigs three weeks of age or older and breeding females. Boehringer Ingelheim maintains a broad PRRS portfolio including Ingelvac PRRS MLV, PRRSFLEX EU, and Reprocyc PRRS EU across PRRSV-1 and PRRSV-2 requirements. Ceva differentiates through the reverse-genetics-based Persoporc platform, while HIPRA combines UNISTRAIN PRRS with 0.2 mL needle-free intradermal vaccination and Smart Vaccination digital technologies. Competition is shifting from conventional strains and dose potency toward heterologous cross-protection, genetic stability, low-volume administration, digital traceability, and integrated herd-control programs. Report Scope This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Swine Live Vaccine market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers. By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern. Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends. Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths. A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand. Market Segmentation By Company Zoetis MSD Animal Health(Merck) Boehringer Ingelheim Ceva Santé Animale Bioveta HIPRA Syva Elanco Animal Health TECON Biology VETVACO Harbin Pharmaceutical Group CAHIC Jinyu Bio-Technology Pulike WINSUN DHN HVRI Jilin Zhengye Wuhan Keqian Biology Sinopharm Animal Health Segment by Type PRRS Vaccines Classical Swine Fever Vaccines Pseudorabies Vaccines Others Segment by Antigen Combination Monovalent Live Vaccines Bivalent Live Vaccines Multivalent Live Vaccines Segment by Dosage Form Lyophilized Live Vaccines Liquid Live Vaccines Others Segment by Application Piglets Growing and Finishing Pigs Breeding Sows and Gilts Breeding Boars Others Segment by Region North America United States Canada Mexico Asia-Pacific China Japan South Korea India Australia Vietnam Indonesia Malaysia Philippines Singapore Rest of Asia Europe Germany U.K. France Italy Spain Benelux Russia Rest of Europe Central and South America Brazil Argentina Rest of Central and South America Middle East & Africa GCC Countries Egypt Israel South Africa Rest of MEA Chapter Outline Chapter 1: Defines the Swine Live Vaccine study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies Chapter 14: Actionable conclusions and strategic recommendations. Why This Report Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to: Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5). Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence. Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11). Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14). Leverage this 360° intelligence to turn market complexity into actionable competitive advantage. Table of Contents1 Study Coverage1.1 Introduction to Swine Live Vaccine: Definition, Properties, and Key Attributes 1.2 Market Segmentation by Type 1.2.1 Global Swine Live Vaccine Market Size by Type, 2021 vs 2025 vs 2032 1.2.2 PRRS Vaccines 1.2.3 Classical Swine Fever Vaccines 1.2.4 Pseudorabies Vaccines 1.2.5 Others 1.3 Market Segmentation by Antigen Combination 1.3.1 Global Swine Live Vaccine Market Size by Antigen Combination, 2021 vs 2025 vs 2032 1.3.2 Monovalent Live Vaccines 1.3.3 Bivalent Live Vaccines 1.3.4 Multivalent Live Vaccines 1.4 Market Segmentation by Dosage Form 1.4.1 Global Swine Live Vaccine Market Size by Dosage Form, 2021 vs 2025 vs 2032 1.4.2 Lyophilized Live Vaccines 1.4.3 Liquid Live Vaccines 1.4.4 Others 1.5 Market Segmentation by Application 1.5.1 Global Swine Live Vaccine Market Size by Application, 2021 vs 2025 vs 2032 1.5.2 Piglets 1.5.3 Growing and Finishing Pigs 1.5.4 Breeding Sows and Gilts 1.5.5 Breeding Boars 1.5.6 Others 1.6 Assumptions and Limitations 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Swine Live Vaccine Revenue Estimates and Forecasts (2021-2032) 2.2 Global Swine Live Vaccine Revenue by Region 2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032 2.2.2 Historical and Forecasted Revenue by Region (2021-2032) 2.2.3 Global Revenue-Based Market Share by Region (2021-2032) 2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends 3 Competitive Landscape 3.1 Global Swine Live Vaccine Players’ Revenue Rankings and Profitability 3.1.1 Global Revenue (Value) by Players (2021-2026) 3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025) 3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3) 3.1.4 Gross Margin by Top Players (2021 vs 2025) 3.2 Global Swine Live Vaccine Companies Headquarters and Service Footprint 3.3 Key Player Market Share by Product Type 3.3.1 PRRS Vaccines: Market Share by Key Players 3.3.2 Classical Swine Fever Vaccines: Market Share by Key Players 3.3.3 Pseudorabies Vaccines: Market Share by Key Players 3.3.4 Others: Market Share by Key Players 3.4 Global Swine Live Vaccine Market Concentration and Dynamics 3.4.1 Global Market Concentration 3.4.2 Market Entry and Exit Analysis 3.4.3 Strategic Moves: M&A, Expansion, R&D Investment 4 Product Segmentation 4.1 Global Swine Live Vaccine Market by Type 4.1.1 Global Revenue by Type (2021-2032) 4.1.2 Global Revenue-Based Market Share by Type (2021-2032) 4.2 Global Swine Live Vaccine Market by Antigen Combination 4.2.1 Global Revenue by Antigen Combination (2021-2032) 4.2.2 Global Revenue-Based Market Share by Antigen Combination (2021-2032) 4.3 Global Swine Live Vaccine Market by Dosage Form 4.3.1 Global Revenue by Dosage Form (2021-2032) 4.3.2 Global Revenue-Based Market Share by Dosage Form (2021-2032) 4.4 Key Product Attributes and Differentiation 4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk 4.5.1 High-Growth Niches and Adoption Drivers 4.5.2 Profitability Hotspots and Cost Drivers 4.5.3 Substitution Threats 5 Downstream Applications and Customers 5.1 Global Swine Live Vaccine Revenue by Application 5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032) 5.1.2 Revenue-Based Market Share by Application (2021-2032) 5.1.3 High-Growth Application Identification 5.1.4 Emerging Application Case Studies 5.2 Downstream Customer Analysis 5.2.1 Top Customers by Region 5.2.2 Top Customers by Application 6 North America 6.1 North America Market Size (2021-2032) 6.2 North America Key Players’ Revenue in 2025 6.3 North America Swine Live Vaccine Market Size by Application (2021-2032) 6.4 North America Growth Accelerators and Market Barriers 6.5 North America Swine Live Vaccine Market Size by Country 6.5.1 North America Revenue Trends by Country 6.5.2 US 6.5.3 Canada 6.5.4 Mexico 7 Europe 7.1 Europe Market Size (2021-2032) 7.2 Europe Key Players’ Revenue in 2025 7.3 Europe Swine Live Vaccine Market Size by Application (2021-2032) 7.4 Europe Growth Accelerators and Market Barriers 7.5 Europe Swine Live Vaccine Market Size by Country 7.5.1 Europe Revenue Trends by Country 7.5.2 Germany 7.5.3 France 7.5.4 U.K. 7.5.5 Italy 7.5.6 Russia 8 Asia-Pacific 8.1 Asia-Pacific Market Size (2021-2032) 8.2 Asia-Pacific Key Players’ Revenue in 2025 8.3 Asia-Pacific Swine Live Vaccine Market Size by Application (2021-2032) 8.4 Asia-Pacific Growth Accelerators and Market Barriers 8.5 Asia-Pacific Swine Live Vaccine Market Size by Region 8.5.1 Asia-Pacific Revenue Trends by Region 8.6 China 8.7 Japan 8.8 South Korea 8.9 Australia 8.10 India 8.11 Southeast Asia 8.11.1 Indonesia 8.11.2 Vietnam 8.11.3 Malaysia 8.11.4 Philippines 8.11.5 Singapore 9 Central and South America 9.1 Central and South America Market Size (2021-2032) 9.2 Central and South America Key Players’ Revenue in 2025 9.3 Central and South America Swine Live Vaccine Market Size by Application (2021-2032) 9.4 Central and South America Investment Opportunities and Key Challenges 9.5 Central and South America Swine Live Vaccine Market Size by Country 9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032) 9.5.2 Brazil 9.5.3 Argentina 10 Middle East and Africa 10.1 Middle East and Africa Market Size (2021-2032) 10.2 Middle East and Africa Key Players’ Revenue in 2025 10.3 Middle East and Africa Swine Live Vaccine Market Size by Application (2021-2032) 10.4 Middle East and Africa Investment Opportunities and Key Challenges 10.5 Middle East and Africa Swine Live Vaccine Market Size by Country 10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032) 10.5.2 GCC Countries 10.5.3 Israel 10.5.4 Egypt 10.5.5 South Africa 11 Corporate Profile 11.1 Zoetis 11.1.1 Zoetis Corporation Information 11.1.2 Zoetis Business Overview 11.1.3 Zoetis Swine Live Vaccine Product Features and Attributes 11.1.4 Zoetis Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.1.5 Zoetis Swine Live Vaccine Revenue by Product in 2025 11.1.6 Zoetis Swine Live Vaccine Revenue by Application in 2025 11.1.7 Zoetis Swine Live Vaccine Revenue by Geographic Area in 2025 11.1.8 Zoetis Swine Live Vaccine SWOT Analysis 11.1.9 Zoetis Recent Developments 11.2 MSD Animal Health(Merck) 11.2.1 MSD Animal Health(Merck) Corporation Information 11.2.2 MSD Animal Health(Merck) Business Overview 11.2.3 MSD Animal Health(Merck) Swine Live Vaccine Product Features and Attributes 11.2.4 MSD Animal Health(Merck) Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.2.5 MSD Animal Health(Merck) Swine Live Vaccine Revenue by Product in 2025 11.2.6 MSD Animal Health(Merck) Swine Live Vaccine Revenue by Application in 2025 11.2.7 MSD Animal Health(Merck) Swine Live Vaccine Revenue by Geographic Area in 2025 11.2.8 MSD Animal Health(Merck) Swine Live Vaccine SWOT Analysis 11.2.9 MSD Animal Health(Merck) Recent Developments 11.3 Boehringer Ingelheim 11.3.1 Boehringer Ingelheim Corporation Information 11.3.2 Boehringer Ingelheim Business Overview 11.3.3 Boehringer Ingelheim Swine Live Vaccine Product Features and Attributes 11.3.4 Boehringer Ingelheim Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.3.5 Boehringer Ingelheim Swine Live Vaccine Revenue by Product in 2025 11.3.6 Boehringer Ingelheim Swine Live Vaccine Revenue by Application in 2025 11.3.7 Boehringer Ingelheim Swine Live Vaccine Revenue by Geographic Area in 2025 11.3.8 Boehringer Ingelheim Swine Live Vaccine SWOT Analysis 11.3.9 Boehringer Ingelheim Recent Developments 11.4 Ceva Santé Animale 11.4.1 Ceva Santé Animale Corporation Information 11.4.2 Ceva Santé Animale Business Overview 11.4.3 Ceva Santé Animale Swine Live Vaccine Product Features and Attributes 11.4.4 Ceva Santé Animale Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.4.5 Ceva Santé Animale Swine Live Vaccine Revenue by Product in 2025 11.4.6 Ceva Santé Animale Swine Live Vaccine Revenue by Application in 2025 11.4.7 Ceva Santé Animale Swine Live Vaccine Revenue by Geographic Area in 2025 11.4.8 Ceva Santé Animale Swine Live Vaccine SWOT Analysis 11.4.9 Ceva Santé Animale Recent Developments 11.5 Bioveta 11.5.1 Bioveta Corporation Information 11.5.2 Bioveta Business Overview 11.5.3 Bioveta Swine Live Vaccine Product Features and Attributes 11.5.4 Bioveta Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.5.5 Bioveta Swine Live Vaccine Revenue by Product in 2025 11.5.6 Bioveta Swine Live Vaccine Revenue by Application in 2025 11.5.7 Bioveta Swine Live Vaccine Revenue by Geographic Area in 2025 11.5.8 Bioveta Swine Live Vaccine SWOT Analysis 11.5.9 Bioveta Recent Developments 11.6 HIPRA 11.6.1 HIPRA Corporation Information 11.6.2 HIPRA Business Overview 11.6.3 HIPRA Swine Live Vaccine Product Features and Attributes 11.6.4 HIPRA Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.6.5 HIPRA Recent Developments 11.7 Syva 11.7.1 Syva Corporation Information 11.7.2 Syva Business Overview 11.7.3 Syva Swine Live Vaccine Product Features and Attributes 11.7.4 Syva Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.7.5 Syva Recent Developments 11.8 Elanco Animal Health 11.8.1 Elanco Animal Health Corporation Information 11.8.2 Elanco Animal Health Business Overview 11.8.3 Elanco Animal Health Swine Live Vaccine Product Features and Attributes 11.8.4 Elanco Animal Health Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.8.5 Elanco Animal Health Recent Developments 11.9 TECON Biology 11.9.1 TECON Biology Corporation Information 11.9.2 TECON Biology Business Overview 11.9.3 TECON Biology Swine Live Vaccine Product Features and Attributes 11.9.4 TECON Biology Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.9.5 TECON Biology Recent Developments 11.10 VETVACO 11.10.1 VETVACO Corporation Information 11.10.2 VETVACO Business Overview 11.10.3 VETVACO Swine Live Vaccine Product Features and Attributes 11.10.4 VETVACO Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.10.5 Company Ten Recent Developments 11.11 Harbin Pharmaceutical Group 11.11.1 Harbin Pharmaceutical Group Corporation Information 11.11.2 Harbin Pharmaceutical Group Business Overview 11.11.3 Harbin Pharmaceutical Group Swine Live Vaccine Product Features and Attributes 11.11.4 Harbin Pharmaceutical Group Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.11.5 Harbin Pharmaceutical Group Recent Developments 11.12 CAHIC 11.12.1 CAHIC Corporation Information 11.12.2 CAHIC Business Overview 11.12.3 CAHIC Swine Live Vaccine Product Features and Attributes 11.12.4 CAHIC Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.12.5 CAHIC Recent Developments 11.13 Jinyu Bio-Technology 11.13.1 Jinyu Bio-Technology Corporation Information 11.13.2 Jinyu Bio-Technology Business Overview 11.13.3 Jinyu Bio-Technology Swine Live Vaccine Product Features and Attributes 11.13.4 Jinyu Bio-Technology Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.13.5 Jinyu Bio-Technology Recent Developments 11.14 Pulike 11.14.1 Pulike Corporation Information 11.14.2 Pulike Business Overview 11.14.3 Pulike Swine Live Vaccine Product Features and Attributes 11.14.4 Pulike Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.14.5 Pulike Recent Developments 11.15 WINSUN 11.15.1 WINSUN Corporation Information 11.15.2 WINSUN Business Overview 11.15.3 WINSUN Swine Live Vaccine Product Features and Attributes 11.15.4 WINSUN Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.15.5 WINSUN Recent Developments 11.16 DHN 11.16.1 DHN Corporation Information 11.16.2 DHN Business Overview 11.16.3 DHN Swine Live Vaccine Product Features and Attributes 11.16.4 DHN Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.16.5 DHN Recent Developments 11.17 HVRI 11.17.1 HVRI Corporation Information 11.17.2 HVRI Business Overview 11.17.3 HVRI Swine Live Vaccine Product Features and Attributes 11.17.4 HVRI Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.17.5 HVRI Recent Developments 11.18 Jilin Zhengye 11.18.1 Jilin Zhengye Corporation Information 11.18.2 Jilin Zhengye Business Overview 11.18.3 Jilin Zhengye Swine Live Vaccine Product Features and Attributes 11.18.4 Jilin Zhengye Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.18.5 Jilin Zhengye Recent Developments 11.19 Wuhan Keqian Biology 11.19.1 Wuhan Keqian Biology Corporation Information 11.19.2 Wuhan Keqian Biology Business Overview 11.19.3 Wuhan Keqian Biology Swine Live Vaccine Product Features and Attributes 11.19.4 Wuhan Keqian Biology Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.19.5 Wuhan Keqian Biology Recent Developments 11.20 Sinopharm Animal Health 11.20.1 Sinopharm Animal Health Corporation Information 11.20.2 Sinopharm Animal Health Business Overview 11.20.3 Sinopharm Animal Health Swine Live Vaccine Product Features and Attributes 11.20.4 Sinopharm Animal Health Swine Live Vaccine Revenue and Gross Margin (2021-2026) 11.20.5 Sinopharm Animal Health Recent Developments 12 Swine Live Vaccine Value Chain and Ecosystem Analysis 12.1 Swine Live Vaccine Value Chain (Ecosystem Structure) 12.2 Upstream Analysis 12.2.1 Key Technologies, Platforms and Infrastructure 12.3 Midstream Analysis 12.4 Downstream Sales Model and Distribution Networks 12.4.1 Sales Channels 12.4.2 Distributors 13 Swine Live Vaccine Market Dynamics 13.1 Industry Trends and Evolution 13.2 Market Growth Drivers and Emerging Opportunities 13.3 Market Challenges, Risks, and Restraints 14 Key Findings in the Global Swine Live Vaccine Study 15 Appendix 15.1 Research Methodology 15.1.1 Methodology/Research Approach 15.1.1.1 Research Programs/Design 15.1.1.2 Market Size Estimation 15.1.1.3 Market Breakdown and Data Triangulation 15.1.2 Data Source 15.1.2.1 Secondary Sources 15.1.2.2 Primary Sources 15.2 Author Details List of Tables/GraphsList of TablesTable 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Table 2. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Table 3. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Table 4. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Table 5. Global Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 6. Global Swine Live Vaccine Revenue by Region (US$ Million), 2021-2026 Table 7. Global Swine Live Vaccine Revenue by Region (US$ Million), 2027-2032 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 9. Global Swine Live Vaccine Revenue by Players (US$ Million), 2021-2026 Table 10. Global Swine Live Vaccine Revenue-Based Market Share by Players (2021-2026) Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue) Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Swine Live Vaccine Revenue, 2025 Table 13. Global Swine Live Vaccine Average Gross Margin (%) by Player (2021 vs 2025) Table 14. Global Swine Live Vaccine Companies Headquarters Table 15. Global Swine Live Vaccine Market Concentration Ratio (CR5) Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment Table 18. Global Swine Live Vaccine Revenue by Type (US$ Million), 2021-2026 Table 19. Global Swine Live Vaccine Revenue by Type (US$ Million), 2027-2032 Table 20. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2021-2026 Table 21. Global Swine Live Vaccine Revenue by Antigen Combination (US$ Million), 2027-2032 Table 22. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2021-2026 Table 23. Global Swine Live Vaccine Revenue by Dosage Form (US$ Million), 2027-2032 Table 24. Key Product Attributes and Differentiation Table 25. Global Swine Live Vaccine Revenue by Application (US$ Million), 2021-2026 Table 26. Global Swine Live Vaccine Revenue by Application (US$ Million), 2027-2032 Table 27. Swine Live Vaccine High-Growth Sectors Demand CAGR (2026-2032) Table 28. Top Customers by Region Table 29. Top Customers by Application Table 30. North America Swine Live Vaccine Growth Accelerators and Market Barriers Table 31. North America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 32. Europe Swine Live Vaccine Growth Accelerators and Market Barriers Table 33. Europe Swine Live Vaccine Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million) Table 34. Asia-Pacific Swine Live Vaccine Growth Accelerators and Market Barriers Table 35. Asia-Pacific Swine Live Vaccine Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Table 36. Central and South America Swine Live Vaccine Investment Opportunities and Key Challenges Table 37. Central and South America Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 38. Middle East and Africa Swine Live Vaccine Investment Opportunities and Key Challenges Table 39. Middle East and Africa Swine Live Vaccine Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million) Table 40. Zoetis Corporation Information Table 41. Zoetis Description and Major Businesses Table 42. Zoetis Product Features and Attributes Table 43. Zoetis Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Zoetis Revenue Proportion by Product in 2025 Table 45. Zoetis Revenue Proportion by Application in 2025 Table 46. Zoetis Revenue Proportion by Geographic Area in 2025 Table 47. Zoetis Swine Live Vaccine SWOT Analysis Table 48. Zoetis Recent Developments Table 49. MSD Animal Health(Merck) Corporation Information Table 50. MSD Animal Health(Merck) Description and Major Businesses Table 51. MSD Animal Health(Merck) Product Features and Attributes Table 52. MSD Animal Health(Merck) Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. MSD Animal Health(Merck) Revenue Proportion by Product in 2025 Table 54. MSD Animal Health(Merck) Revenue Proportion by Application in 2025 Table 55. MSD Animal Health(Merck) Revenue Proportion by Geographic Area in 2025 Table 56. MSD Animal Health(Merck) Swine Live Vaccine SWOT Analysis Table 57. MSD Animal Health(Merck) Recent Developments Table 58. Boehringer Ingelheim Corporation Information Table 59. Boehringer Ingelheim Description and Major Businesses Table 60. Boehringer Ingelheim Product Features and Attributes Table 61. Boehringer Ingelheim Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Boehringer Ingelheim Revenue Proportion by Product in 2025 Table 63. Boehringer Ingelheim Revenue Proportion by Application in 2025 Table 64. Boehringer Ingelheim Revenue Proportion by Geographic Area in 2025 Table 65. Boehringer Ingelheim Swine Live Vaccine SWOT Analysis Table 66. Boehringer Ingelheim Recent Developments Table 67. Ceva Santé Animale Corporation Information Table 68. Ceva Santé Animale Description and Major Businesses Table 69. Ceva Santé Animale Product Features and Attributes Table 70. Ceva Santé Animale Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Ceva Santé Animale Revenue Proportion by Product in 2025 Table 72. Ceva Santé Animale Revenue Proportion by Application in 2025 Table 73. Ceva Santé Animale Revenue Proportion by Geographic Area in 2025 Table 74. Ceva Santé Animale Swine Live Vaccine SWOT Analysis Table 75. Ceva Santé Animale Recent Developments Table 76. Bioveta Corporation Information Table 77. Bioveta Description and Major Businesses Table 78. Bioveta Product Features and Attributes Table 79. Bioveta Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Bioveta Revenue Proportion by Product in 2025 Table 81. Bioveta Revenue Proportion by Application in 2025 Table 82. Bioveta Revenue Proportion by Geographic Area in 2025 Table 83. Bioveta Swine Live Vaccine SWOT Analysis Table 84. Bioveta Recent Developments Table 85. HIPRA Corporation Information Table 86. HIPRA Description and Major Businesses Table 87. HIPRA Product Features and Attributes Table 88. HIPRA Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. HIPRA Recent Developments Table 90. Syva Corporation Information Table 91. Syva Description and Major Businesses Table 92. Syva Product Features and Attributes Table 93. Syva Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Syva Recent Developments Table 95. Elanco Animal Health Corporation Information Table 96. Elanco Animal Health Description and Major Businesses Table 97. Elanco Animal Health Product Features and Attributes Table 98. Elanco Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Elanco Animal Health Recent Developments Table 100. TECON Biology Corporation Information Table 101. TECON Biology Description and Major Businesses Table 102. TECON Biology Product Features and Attributes Table 103. TECON Biology Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. TECON Biology Recent Developments Table 105. VETVACO Corporation Information Table 106. VETVACO Description and Major Businesses Table 107. VETVACO Product Features and Attributes Table 108. VETVACO Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. VETVACO Recent Developments Table 110. Harbin Pharmaceutical Group Corporation Information Table 111. Harbin Pharmaceutical Group Description and Major Businesses Table 112. Harbin Pharmaceutical Group Product Features and Attributes Table 113. Harbin Pharmaceutical Group Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Harbin Pharmaceutical Group Recent Developments Table 115. CAHIC Corporation Information Table 116. CAHIC Description and Major Businesses Table 117. CAHIC Product Features and Attributes Table 118. CAHIC Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. CAHIC Recent Developments Table 120. Jinyu Bio-Technology Corporation Information Table 121. Jinyu Bio-Technology Description and Major Businesses Table 122. Jinyu Bio-Technology Product Features and Attributes Table 123. Jinyu Bio-Technology Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Jinyu Bio-Technology Recent Developments Table 125. Pulike Corporation Information Table 126. Pulike Description and Major Businesses Table 127. Pulike Product Features and Attributes Table 128. Pulike Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Pulike Recent Developments Table 130. WINSUN Corporation Information Table 131. WINSUN Description and Major Businesses Table 132. WINSUN Product Features and Attributes Table 133. WINSUN Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. WINSUN Recent Developments Table 135. DHN Corporation Information Table 136. DHN Description and Major Businesses Table 137. DHN Product Features and Attributes Table 138. DHN Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. DHN Recent Developments Table 140. HVRI Corporation Information Table 141. HVRI Description and Major Businesses Table 142. HVRI Product Features and Attributes Table 143. HVRI Revenue (US$ Million) and Gross Margin (2021-2026) Table 144. HVRI Recent Developments Table 145. Jilin Zhengye Corporation Information Table 146. Jilin Zhengye Description and Major Businesses Table 147. Jilin Zhengye Product Features and Attributes Table 148. Jilin Zhengye Revenue (US$ Million) and Gross Margin (2021-2026) Table 149. Jilin Zhengye Recent Developments Table 150. Wuhan Keqian Biology Corporation Information Table 151. Wuhan Keqian Biology Description and Major Businesses Table 152. Wuhan Keqian Biology Product Features and Attributes Table 153. Wuhan Keqian Biology Revenue (US$ Million) and Gross Margin (2021-2026) Table 154. Wuhan Keqian Biology Recent Developments Table 155. Sinopharm Animal Health Corporation Information Table 156. Sinopharm Animal Health Description and Major Businesses Table 157. Sinopharm Animal Health Product Features and Attributes Table 158. Sinopharm Animal Health Revenue (US$ Million) and Gross Margin (2021-2026) Table 159. Sinopharm Animal Health Recent Developments Table 160. Technologies, Platforms and Infrastructure Table 161. Distributors List Table 162. Market Trends and Market Evolution Table 163. Market Drivers and Opportunities Table 164. Market Challenges, Risks, and Restraints Table 165. Research Programs/Design for This Report Table 166. Key Data Information from Secondary Sources Table 167. Key Data Information from Primary Sources List of Figures Figure 1. Global Swine Live Vaccine Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million) Figure 2. PRRS Vaccines Product Picture Figure 3. Classical Swine Fever Vaccines Product Picture Figure 4. Pseudorabies Vaccines Product Picture Figure 5. Others Product Picture Figure 6. Global Swine Live Vaccine Market Size Growth Rate by Antigen Combination, 2021 vs 2025 vs 2032 (US$ Million) Figure 7. Monovalent Live Vaccines Product Picture Figure 8. Bivalent Live Vaccines Product Picture Figure 9. Multivalent Live Vaccines Product Picture Figure 10. Global Swine Live Vaccine Market Size Growth Rate by Dosage Form, 2021 vs 2025 vs 2032 (US$ Million) Figure 11. Lyophilized Live Vaccines Product Picture Figure 12. Liquid Live Vaccines Product Picture Figure 13. Others Product Picture Figure 14. Global Swine Live Vaccine Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million) Figure 15. Piglets Figure 16. Growing and Finishing Pigs Figure 17. Breeding Sows and Gilts Figure 18. Breeding Boars Figure 19. Others Figure 20. Swine Live Vaccine Report Years Considered Figure 21. Global Swine Live Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032 Figure 22. Global Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 23. Global Swine Live Vaccine Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million) Figure 24. Global Swine Live Vaccine Revenue-Based Market Share by Region (2021-2032) Figure 25. Global Swine Live Vaccine Revenue-Based Market Share Ranking (2025) Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025) Figure 27. PRRS Vaccines Revenue-Based Market Share by Player in 2025 Figure 28. Classical Swine Fever Vaccines Revenue-Based Market Share by Player in 2025 Figure 29. Pseudorabies Vaccines Revenue-Based Market Share by Player in 2025 Figure 30. Others Revenue-Based Market Share by Player in 2025 Figure 31. Global Swine Live Vaccine Revenue-Based Market Share by Type (2021-2032) Figure 32. Global Swine Live Vaccine Revenue-Based Market Share by Antigen Combination (2021-2032) Figure 33. Global Swine Live Vaccine Revenue-Based Market Share by Dosage Form (2021-2032) Figure 34. Global Swine Live Vaccine Revenue-Based Market Share by Application (2021-2032) Figure 35. North America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 36. North America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 37. North America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 38. US Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 39. Canada Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 40. Mexico Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 41. Europe Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 42. Europe Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 43. Europe Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 44. Germany Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 45. France Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 46. U.K. Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 47. Italy Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 48. Russia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 49. Asia-Pacific Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 50. Asia-Pacific Top 8 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 51. Asia-Pacific Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 52. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 53. Japan Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 54. South Korea Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 55. Australia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 56. India Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 57. Indonesia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 58. Vietnam Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 59. Malaysia Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 60. Philippines Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 61. Singapore Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 62. Central and South America Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 63. Central and South America Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 64. Central and South America Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 65. Brazil Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 66. Argentina Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 67. Middle East and Africa Swine Live Vaccine Revenue YoY (US$ Million), 2021-2032 Figure 68. Middle East and Africa Top 5 Players Swine Live Vaccine Revenue (US$ Million) in 2025 Figure 69. Middle East and Africa Swine Live Vaccine Revenue (US$ Million) by Application (2021-2032) Figure 70. GCC Countries Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 71. Israel Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 72. Egypt Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 73. South Africa Swine Live Vaccine Revenue (US$ Million), 2021-2032 Figure 74. Swine Live Vaccine Value Chain Mapping Figure 75. Channels of Distribution (Direct Vs Distribution) Figure 76. Bottom-up and Top-down Approaches for This Report Figure 77. Data Triangulation Figure 78. Key Executives Interviewed
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(医療)の最新刊レポートQYResearch社の 医療分野 での最新刊レポート本レポートと同じKEY WORD(swine)の最新刊レポート
よくあるご質問QYResearch社はどのような調査会社ですか?QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。 QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|